UCB selects KabaFusion as a limited distribution partner to provide RYSTIGGO® (rozanolixizumab-noli). RYSTIGGO® (rozanolixizumab-noli) is for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. It is the only FDA-approved treatment in adults for both anti-AChR and anti-MuSK antibody-positive gMG, the two most common subtypes of gMG.1 For more information, please see the Full Prescribing Information for RYSTIGGO®.
“KabaFusion is proud to be a leader in home infusion and providing access to patients with new drugs that will improve their quality of life. We have a well-established history of successfully managing patients with myasthenia gravis and neuromuscular conditions and we are proud to have been selected by UCB as a limited distribution partner to provide RYSTIGGO to patients and providers,” said Dr. Sohail Masood, founder and CEO of KabaFusion.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!